Patents Assigned to INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE
-
Patent number: 11602327Abstract: Method and system for localizing a region of interest in a medium in which cavitation occurs. Method for localizing a region of interest (R) in a medium (M) in which cavitation occurs, the method comprising the steps consisting in: producing cavitation in the region of interest (R), the cavitation generating an acoustic signal, at each of at least three separate positions, detecting a cavitation signal representative of the acoustic signal of the cavitation, for at least two pairs of cavitation signals, determining a delay between the cavitation signals of each pair of cavitation signals, calculating a localization of the region of interest (R) based on the delays and the positions.Type: GrantFiled: August 28, 2017Date of Patent: March 14, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD LYON 1, TOHOKU UNIVERSITYInventors: Cyril Lafon, Jean-Louis Mestas, Maxime Lafond, Shin-Ichiro Umemura
-
Patent number: 11596698Abstract: The present invention concerns synthetic polynucleotides encoding a human fukutin-related protein (FKRP) wherein the synthetic polynucleotides contain at least a mutation avoiding supplementary transcript(s) generated from frameshift start codon(s). The synthetic polynucleotides are useful, especially for treating a pathology linked to a FKRP deficiency or induced by a defect in ?-dystroglycan (?-DG) glycosylation, such as LGMD2I.Type: GrantFiled: July 6, 2018Date of Patent: March 7, 2023Assignees: GENETHON, UNIVERSITE D'EVRY-VAL-D'ESSONNE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: Isabelle Richard, Evelyne Gicquel-Zouida, William Lostal
-
Patent number: 11597777Abstract: The invention relates to an isolated monoclonal antibody that specifically binds to the D4 domain of VWF, competes for binding to VWF D4 domain with ADAMTS13 and partially inhibits ADAMTS 13-mediated degradation of VWF. More particularly, the invention relates to an isolated monoclonal antibody comprising a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 3 for H-CDR1, SEQ ID NO: 4 for H-CDR2 and SEQ ID NO: 5 for H-CDR3 and a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 7 for L-CDR1, SEQ ID NO: 8 for L-CDR2 and SEQ ID NO: 9 for L-CDR3. Antibodies of the invention are presented to be useful in for the prevention or the treatment of bleeding episodes, such as bleeding episodes occurring in patients with aortic stenosis or patients with ventricular assist devices (VAD).Type: GrantFiled: December 10, 2019Date of Patent: March 7, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDECALE), UNIVERSITE PARIS—SUD, CENTRE HOSPITALIER REGIONALE UNIVERSITAIRE DE LILLE, UNIVERSITÉ DE DROIT ET DE LA SANTÉ DE LILLE 2Inventors: Petrus Lenting, Cécile Denis, Olivier Christophe, Paulette Legendre, Antoine Rauch, Sophie Susen
-
Patent number: 11583596Abstract: The present inventors have developed new radiolabeled Darapladib and analogs thereof which can be used for the specific detection of vulnerable atherosclerotic plaques by targeting lipoprotein-associated phospholipase A2 (Lp-PLA2) which is a biomarker of choice concerning inflammation and atherosclerosis progression. Thus, the present invention relates to radiolabeled Darapladib and analogs thereof and their use as imaging compounds.Type: GrantFiled: September 26, 2018Date of Patent: February 21, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LA REUNIONInventors: Olivier Meilhac, Emmanuelle Jestin, Florian Guibbal, Sébastien Benard
-
Patent number: 11579147Abstract: Sarcomas are rare malignant tumors arising from the mesenchymal tissues at all body sites. The inventors show that in a mouse model of p16/p19 deficiency prone to tumor development, the absence of the mouse pantetheinase Vnn1 enhances the frequency of aggressive fibrosarcomas. They also show that reintroduction of a catalytically active form of the Vnn1 pantetheinase limits tumor growth in vivo. Interestingly, VNN1 expression in human sarcomas is associated with reduced aggressiveness and lower risk of metastatic relapse in patients. In conclusion, Vnn1 represents a novel marker of sarcoma and may modulate tumor aggressiveness by sustaining myofibroblast cell differentiation, thereby limiting evolution towards undifferentiated tumors. The present invention relates to the use of Vnn1 as a biomarker and a therapeutic target in sarcomas.Type: GrantFiled: September 25, 2018Date of Patent: February 14, 2023Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université d'Aix Marseille, Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard, Centre Leon BernardInventors: Philippe Naquet, Franck Galland, Virginie Millet, Jean-Yves Blay, Caroline Giessner
-
Patent number: 11559566Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.Type: GrantFiled: July 10, 2020Date of Patent: January 24, 2023Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, SORBONNE UNIVERSITEInventors: David Klatzmann, David Saadoun, Patrice Cacoub, Michèle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard
-
Patent number: 11560436Abstract: The invention relates to isolated single-domain antibodies (sdAb) directed against von Willebrand Factor (VWF) D?D3 domain and chimeric polypeptides comprising thereof such as blood clotting factors and their uses in therapy such as in the prevention and treatment of hemostatic disorders. The invention also relates to a method of extending or increasing half-life of a therapeutic polypeptide comprising a step of adding to the polypeptide sequence of said therapeutic polypeptide at least one sdAb directed against VWF D?D3 domain.Type: GrantFiled: March 13, 2020Date of Patent: January 24, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS-SACLAYInventors: Petrus Lenting, Gabriel Ayme, Cecile Denis, Olivier Christophe
-
Patent number: 11559244Abstract: Disclosed is a method for the generation of a consciousness indicator for a non-communicating subject, including the steps of generating an auditory stimulation, receiving an electrocardiographic signal of the subject obtained from a recording during the generation of the auditory stimulation, extracting at least one feature from the electrocardiographic signal and deducing a consciousness indicator from an analysis of the electrocardiographic feature.Type: GrantFiled: September 11, 2018Date of Patent: January 24, 2023Assignees: ICM—INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CNRS (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE), APHP, SORBONNE UNIVERSITÉInventors: Federico Raimondo, Jacobo D Sitt, Lionel Naccache, Diego Fernandez Slezak
-
Publication number: 20230021272Abstract: A vibrotactile stimulation device intended to be applied against a body medium (MC) to be stimulated, produced in the form of a functional unit, comprising a vibrating effector suitable for applying, to said medium, pulses of mechanical vibrational energy, and a controller for controlling the effector according to stimulation rules. The functional unit further houses a first electrode suitable for cooperating with at least one second electrode separated from the first electrode in order to supply signals representative of a cardiac activity and a muscular activity on the medium to be stimulated, said controller being sensitive to cardiac activity and muscular activity signals in order to influence the stimulation. The stimulation device may be used for body stimulation in combating sleep apnea, with improved detection.Type: ApplicationFiled: September 29, 2022Publication date: January 19, 2023Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE RENNES IInventor: Alfredo HERNANDEZ
-
Publication number: 20220411493Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. The tight junction protein claudin-1 (CLDN1) is an essential entry factor for HCV and a promising target for therapy. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). The inventors also demonstrate that anti-CLDN1 H3L3 cures persistent HCV infection in human-liver chimeric uPA-SCID mice in monotherapy.Type: ApplicationFiled: April 29, 2022Publication date: December 29, 2022Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de StrasbourgInventors: Thomas BAUMERT, Rajeevkumar Tawar
-
Patent number: 11530241Abstract: The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.Type: GrantFiled: December 14, 2018Date of Patent: December 20, 2022Assignees: UNIVERSITE DE STRASBOURG, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALEInventor: Vincent Marion
-
Publication number: 20220396773Abstract: A method of obtaining 3D cell structures including differentiated human hepatic cells. The method includes: a first step of culturing stem cell-derived or immortalized human hepatic progenitors in a non-adherent culture vessel, preferably a low or ultra-low attachment culture vessel; a second step of transferring the stem cell-derived or immortalized human hepatic progenitors to a culture medium including methacrylated gelatin (GelMa), thereby embedding the stem cell-derived or immortalized human hepatic progenitors in a GelMa matrix; and a third step of covering the GelMa matrix with culture medium and culturing the stem cell-derived or immortalized human hepatic progenitors embedded in the GelMa matrix, thereby obtaining 3D cell structures including differentiated human hepatic cells. Also, methods for engineering an artificial liver model or an artificial liver organ, and for assessing in vitro the metabolism, toxicity and/or therapeutic effects of a compound.Type: ApplicationFiled: November 13, 2020Publication date: December 15, 2022Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE RENNES 1, ÉCOLE DES HAUTES ÉTUDES EN SANTÉ PUBLIQUE (EHESP)Inventors: Georges BAFFET, Marie CUVELLIER, Frédéric EZAN, Sophie ROSE
-
Patent number: 11525008Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of lung cancer. The inventors showed that FHIT (also known as bis(5-adenosyl)-triphosphatase) regulates HER2 activity in lung tumor cells and that HER2 inhibitors reduce invasion induced by FHIT inhibition. In particular, the present invention relates to a method of treating lung cancer in a patient in need thereof comprising the steps of i) determining the expression level of FHIT in a tumor tissue sample obtained from the patient, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) administering to the patient a therapeutically effective amount of at least one HER2 inhibitor when the expression level determined at step i) is lower than the predetermined reference level.Type: GrantFiled: September 21, 2017Date of Patent: December 13, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE REIMS CHAMPAGNE-ARDENNE, CENTRE HOSPITALIER UNIVERSITAIRE DE REIMSInventors: Béatrice Raby, Amina Jouida, Myriam Polette
-
Patent number: 11511016Abstract: The present invention relates to a method for preparing a porous scaffold for tissue engineering. It is another object of the present invention to provide a porous scaffold obtainable by the method as above described, and its use for tissue engineering, cell culture and cell delivery. The method of the invention comprises the steps consisting of: a) preparing an alkaline aqueous solution comprising an amount of at least one polysaccharide, an amount of a cross-linking agent and an amount of a porogen agent b) transforming the solution into a hydrogel by placing said solution at a temperature from about 4° C. to about 80° C. for a sufficient time to allow the cross-linking of said amount of polysaccharide and c) submerging said hydrogel into an aqueous solution d) washing the porous scaffold obtained at step c).Type: GrantFiled: March 25, 2019Date of Patent: November 29, 2022Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris CitéInventors: Catherine Le Visage, Didier Letourneur
-
Patent number: 11504094Abstract: An apparatus and a method for contrast-enhanced ultrasound (CEUS) including use of a fluid dynamics model for the analysis of dynamic contrast-enhanced ultrasound (DCEUS).Type: GrantFiled: July 27, 2018Date of Patent: November 22, 2022Assignees: (INSERM) INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ DE TOURS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE BORDEAUX, INSTITUT POLYTECHNIQUE DE BORDEAUX (IPB)Inventors: Baudouin Denis de Senneville, Franck Perrotin, Jean-Michel Escoffre, Ayache Bouakaz
-
Publication number: 20220361896Abstract: A medical device for penetrating a bone structure including a processing unit having a transfer function that associates an electrical conductivity value S with a depth value d, wherein the processing unit is configured to detect a threshold selected from amongst an absolute threshold, a relative threshold and a critical gradient, and to emit a warning signal and/or control signal responsive to detection of the threshold.Type: ApplicationFiled: May 2, 2022Publication date: November 17, 2022Applicants: SpineGuard, Sorbonne Universite, Centre National de la Recherche Scientifique - CNRS, INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Stephane BETTE, Jimmy DA SILVA, Thibault CHANDANSON, Guillaume MOREL, Maurice BOURLION
-
Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies
Patent number: 11499154Abstract: The present invention concerns the use of antisense oligonucleotides (AON) capable of inhibiting expression of dynamin 2, advantageously human dynamin 2, for use in the treatment of Charcot-Marie-Tooth disease (CMT) and centronuclear myopathies (CNM).Type: GrantFiled: April 10, 2018Date of Patent: November 15, 2022Assignees: GENETHON, UNIVERSITE D'EVRY-VAL-D'ESSONNE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventor: Ana Maria Buj Bello -
Patent number: 11484537Abstract: The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a Cannabinoids-Related Disorder. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of a Cannabinoids-Related Disorder. Indeed, the compound of the invention is in vivo very potent in inhibiting the effects of THC, and is able to inhibit both unconditioned and conditioned effects of THC including THC self-administration and reinstatement in THC seeking in non-human primates.Type: GrantFiled: February 20, 2019Date of Patent: November 1, 2022Assignees: AELIS FARMA, INSERM (Institut National de la Santé et de la Recherche Médicale), UNIVERSITE DE BORDEAUXInventors: Pier Vincenzo Piazza, Sandy Fabre, Mathilde Metna, Stéphanie Monlezun, Arnau Busquet-Garcia, Daniela Cota, Giovanni Marsicano, Jean-Michel Revest, Monique Vallée
-
Patent number: 11484577Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction. In particular, the present invention relates to a method of treating post-operative cognitive dysfunction in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an APJ receptor agonist.Type: GrantFiled: February 14, 2017Date of Patent: November 1, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Philippe Valet, Cedric Dray, Vincent Minville, Bernard Frances, Francois Labaste, Claire Vinel
-
Patent number: 11479817Abstract: The present invention relates to a method for discriminating an operationally tolerant (TOL) subject from a non-operationally tolerant (STA) subject, comprising the following steps: i) establishing a composite score of tolerance (cSoT) with the expression levels of six genes in a biological sample obtained from said subject and two clinical parameters; wherein said six genes are ID3, AKR1C3, CD40, CTLA4, TCL1A and MZB1, and wherein said cSoT is established by the following formula: cSoT = ? i n ? = ? i × Exprs + ? test ? ? time × age test ? ? time + ? trans ? ? time × age trans ? ? time + intercept - scaling ? ? coefficient ii) comparing this cSoT with a predetermined reference value; and iii) concluding that the subject is TOL when the cSoT is higher than the predetermined reference value or concluding that the subject is STA when the cSoT is lower than the predetermined reference value.Type: GrantFiled: July 21, 2017Date of Patent: October 25, 2022Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, Université de Nantes, Centre Hospitalier Universitaire de Nantes, Centre National de la Recherche ScientifiqueInventors: Richard Danger, Sophie Brouard, Magali Giral, Gérard Ramstein